103 related articles for article (PubMed ID: 31612791)
1. Binding mode of Pyridoclax to myeloid cell leukemia-1 (Mcl-1) revealed by nuclear magnetic resonance spectroscopy, docking and molecular dynamics approaches.
Bourafai-Aziez A; Sebban M; Benabderrahmane M; Marekha B; Denis C; Paysant H; Weiswald LB; Carlier L; Bureau R; Coadou G; Ravault D; Voisin-Chiret AS; Sopková-de Oliveira Santos J; Oulyadi H
J Biomol Struct Dyn; 2020 Sep; 38(14):4162-4178. PubMed ID: 31612791
[TBL] [Abstract][Full Text] [Related]
2. Structure-guided design of pyridoclax derivatives based on Noxa / Mcl-1 interaction mode.
Hedir S; De Giorgi M; Fogha J; De Pascale M; Weiswald LB; Brotin E; Marekha B; Denoyelle C; Denis C; Suzanne P; Gautier F; Juin P; Ligat L; Lopez F; Carlier L; Legay R; Bureau R; Rault S; Poulain L; Oliveira Santos JS; Voisin-Chiret AS
Eur J Med Chem; 2018 Nov; 159():357-380. PubMed ID: 30308410
[TBL] [Abstract][Full Text] [Related]
3. Molecular dynamic simulations on an inhibitor of anti-apoptotic Bcl-2 proteins for insights into its interaction mechanism for anti-cancer activity.
Anantram A; Kundaikar H; Degani M; Prabhu A
J Biomol Struct Dyn; 2019 Aug; 37(12):3109-3121. PubMed ID: 30526410
[TBL] [Abstract][Full Text] [Related]
4. Binding affinity of pro-apoptotic BH3 peptides for the anti-apoptotic Mcl-1 and A1 proteins: Molecular dynamics simulations of Mcl-1 and A1 in complex with six different BH3 peptides.
Modi V; Sankararamakrishnan R
J Mol Graph Model; 2017 May; 73():115-128. PubMed ID: 28279820
[TBL] [Abstract][Full Text] [Related]
5. Toward Understanding Mcl-1 Promiscuous and Specific Binding Mode.
Fogha J; Marekha B; De Giorgi M; Voisin-Chiret AS; Rault S; Bureau R; Sopkova-de Oliveira Santos J
J Chem Inf Model; 2017 Nov; 57(11):2885-2895. PubMed ID: 29016132
[TBL] [Abstract][Full Text] [Related]
6. First evidence that oligopyridines, α-helix foldamers, inhibit Mcl-1 and sensitize ovarian carcinoma cells to Bcl-xL-targeting strategies.
Gloaguen C; Voisin-Chiret AS; Sopkova-de Oliveira Santos J; Fogha J; Gautier F; De Giorgi M; Burzicki G; Perato S; Pétigny-Lechartier C; Simonin-Le Jeune K; Brotin E; Goux D; N'Diaye M; Lambert B; Louis MH; Ligat L; Lopez F; Juin P; Bureau R; Rault S; Poulain L
J Med Chem; 2015 Feb; 58(4):1644-68. PubMed ID: 25585174
[TBL] [Abstract][Full Text] [Related]
7. Solution structure of prosurvival Mcl-1 and characterization of its binding by proapoptotic BH3-only ligands.
Day CL; Chen L; Richardson SJ; Harrison PJ; Huang DC; Hinds MG
J Biol Chem; 2005 Feb; 280(6):4738-44. PubMed ID: 15550399
[TBL] [Abstract][Full Text] [Related]
8. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.
Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z
Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174
[TBL] [Abstract][Full Text] [Related]
9. Computational Design of BH3-Mimetic Peptide Inhibitors That Can Bind Specifically to Mcl-1 or Bcl-X
Reddy CN; Manzar N; Ateeq B; Sankararamakrishnan R
Biochemistry; 2020 Nov; 59(45):4379-4394. PubMed ID: 33146015
[TBL] [Abstract][Full Text] [Related]
10. Molecular dynamics study of segment peptides of Bax, Bim, and Mcl-1 BH3 domain of the apoptosis-regulating proteins bound to the anti-apoptotic Mcl-1 protein.
Zhao RN; Fan S; Han JG; Liu G
J Biomol Struct Dyn; 2015; 33(5):1067-81. PubMed ID: 24865469
[TBL] [Abstract][Full Text] [Related]
11. Allosteric inhibition of antiapoptotic MCL-1.
Lee S; Wales TE; Escudero S; Cohen DT; Luccarelli J; Gallagher CG; Cohen NA; Huhn AJ; Bird GH; Engen JR; Walensky LD
Nat Struct Mol Biol; 2016 Jun; 23(6):600-7. PubMed ID: 27159560
[TBL] [Abstract][Full Text] [Related]
12. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
[TBL] [Abstract][Full Text] [Related]
13. The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
Pétigny-Lechartier C; Duboc C; Jebahi A; Louis MH; Abeilard E; Denoyelle C; Gauduchon P; Poulain L; Villedieu M
Mol Cancer Ther; 2017 Jan; 16(1):102-115. PubMed ID: 27980105
[TBL] [Abstract][Full Text] [Related]
14. Discovery of small molecule inhibitors through pharmacophore modeling, molecular docking, molecular dynamics simulation and experimental validation against myeloid cell leukemia-1 (Mcl-1).
Suleiman MR; Wang H; Huang D; Wang H; Joseph J; Huang T; Zhang F; Wang J; Cheng M
J Biomol Struct Dyn; 2021 Apr; 39(7):2512-2525. PubMed ID: 32228162
[TBL] [Abstract][Full Text] [Related]
15. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
[TBL] [Abstract][Full Text] [Related]
16. Kröhnke pyridines: Rapid and facile access to Mcl-1 inhibitors.
Conlon IL; Van Eker D; Abdelmalak S; Murphy WA; Bashir H; Sun M; Chauhan J; Varney KM; Godoy-Ruiz R; Wilder PT; Fletcher S
Bioorg Med Chem Lett; 2018 Jun; 28(10):1949-1953. PubMed ID: 29705141
[TBL] [Abstract][Full Text] [Related]
17. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
18. Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells.
Doi K; Gowda K; Liu Q; Lin JM; Sung SS; Dower C; Claxton D; Loughran TP; Amin S; Wang HG
Cancer Biol Ther; 2014; 15(12):1688-99. PubMed ID: 25535900
[TBL] [Abstract][Full Text] [Related]
19. Structural basis for the conserved binding mechanism of MDM2-inhibiting peptides and anti-apoptotic Bcl-2 family proteins.
Lee MS; Ha JH; Yoon HS; Lee CK; Chi SW
Biochem Biophys Res Commun; 2014 Feb; 445(1):120-5. PubMed ID: 24491548
[TBL] [Abstract][Full Text] [Related]
20. Discovery of selective Mcl-1 inhibitors via structure-based design and structure-activity relationship analysis.
He N; Liu P; Wang Z; Guo Z; Yan X; Chen H; Zhang Z
Biochem Biophys Res Commun; 2019 May; 512(4):921-926. PubMed ID: 30928099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
